Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Phase 2 Recruiting 40 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.

Timeline

Start: 2024-05-29
Primary completion: 2026-01-10
Completion: 2026-07-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sodium Glycididazole	Small molecule	800 mg	Intravenous

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Summary

Timeline

Drugs

Indications